|

Allogeneic T cell progenitors, cultured ex-vivo Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since July 2026

Also known as: SMART101

Pipeline

Phase 1/2: 1

Top Sponsors

  • Smart Immune SAS1

Indications

  • Hematological Malignancies1
  • Cancer1

New York, New York1 trial

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

Memorial Sloan Kettering Cancer Center (MSKCC)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.